328 related articles for article (PubMed ID: 28160557)
1. Cancer-associated oxidoreductase ERO1-α promotes immune escape through up-regulation of PD-L1 in human breast cancer.
Tanaka T; Kutomi G; Kajiwara T; Kukita K; Kochin V; Kanaseki T; Tsukahara T; Hirohashi Y; Torigoe T; Okamoto Y; Hirata K; Sato N; Tamura Y
Oncotarget; 2017 Apr; 8(15):24706-24718. PubMed ID: 28160557
[TBL] [Abstract][Full Text] [Related]
2. Cancer-associated oxidoreductase ERO1-α drives the production of tumor-promoting myeloid-derived suppressor cells via oxidative protein folding.
Tanaka T; Kajiwara T; Torigoe T; Okamoto Y; Sato N; Tamura Y
J Immunol; 2015 Feb; 194(4):2004-10. PubMed ID: 25595776
[TBL] [Abstract][Full Text] [Related]
3. Cancer-associated oxidoreductase ERO1-α drives the production of VEGF via oxidative protein folding and regulating the mRNA level.
Tanaka T; Kutomi G; Kajiwara T; Kukita K; Kochin V; Kanaseki T; Tsukahara T; Hirohashi Y; Torigoe T; Okamoto Y; Hirata K; Sato N; Tamura Y
Br J Cancer; 2016 May; 114(11):1227-34. PubMed ID: 27100727
[TBL] [Abstract][Full Text] [Related]
4. Endoplasmic reticulum stress-induced exosomal miR-27a-3p promotes immune escape in breast cancer via regulating PD-L1 expression in macrophages.
Yao X; Tu Y; Xu Y; Guo Y; Yao F; Zhang X
J Cell Mol Med; 2020 Sep; 24(17):9560-9573. PubMed ID: 32672418
[TBL] [Abstract][Full Text] [Related]
5. Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression.
Yang WH; Cha JH; Xia W; Lee HH; Chan LC; Wang YN; Hsu JL; Ren G; Hung MC
Cancer Res; 2018 Jul; 78(14):3761-3768. PubMed ID: 29789418
[TBL] [Abstract][Full Text] [Related]
6. Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8
Fang W; Zhou T; Shi H; Yao M; Zhang D; Qian H; Zeng Q; Wang Y; Jin F; Chai C; Chen T
J Exp Clin Cancer Res; 2021 Jan; 40(1):4. PubMed ID: 33390170
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer cells promote CD169
Jing W; Guo X; Wang G; Bi Y; Han L; Zhu Q; Qiu C; Tanaka M; Zhao Y
Int Immunopharmacol; 2020 Jan; 78():106012. PubMed ID: 31865052
[TBL] [Abstract][Full Text] [Related]
8. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.
Barsoum IB; Smallwood CA; Siemens DR; Graham CH
Cancer Res; 2014 Feb; 74(3):665-74. PubMed ID: 24336068
[TBL] [Abstract][Full Text] [Related]
9. PD-1/PD-L1 Pathway in Breast Cancer.
Schütz F; Stefanovic S; Mayer L; von Au A; Domschke C; Sohn C
Oncol Res Treat; 2017; 40(5):294-297. PubMed ID: 28346916
[TBL] [Abstract][Full Text] [Related]
10. Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells.
Coombs MRP; Harrison ME; Hoskin DW
Cancer Lett; 2016 Oct; 380(2):424-433. PubMed ID: 27378243
[TBL] [Abstract][Full Text] [Related]
11. Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation.
Vartuli RL; Zhou H; Zhang L; Powers RK; Klarquist J; Rudra P; Vincent MY; Ghosh D; Costello JC; Kedl RM; Slansky JE; Zhao R; Ford HL
J Clin Invest; 2018 Jun; 128(6):2535-2550. PubMed ID: 29757193
[TBL] [Abstract][Full Text] [Related]
12. Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells.
Yuan LW; Jiang XM; Xu YL; Huang MY; Chen YC; Yu WB; Su MX; Ye ZH; Chen X; Wang Y; Lu JJ
Phytomedicine; 2021 Jan; 80():153394. PubMed ID: 33130472
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
14. Ero1-L alpha plays a key role in a HIF-1-mediated pathway to improve disulfide bond formation and VEGF secretion under hypoxia: implication for cancer.
May D; Itin A; Gal O; Kalinski H; Feinstein E; Keshet E
Oncogene; 2005 Feb; 24(6):1011-20. PubMed ID: 15592500
[TBL] [Abstract][Full Text] [Related]
15. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.
Kurozumi S; Fujii T; Matsumoto H; Inoue K; Kurosumi M; Horiguchi J; Kuwano H
Med Mol Morphol; 2017 Dec; 50(4):185-194. PubMed ID: 28936553
[TBL] [Abstract][Full Text] [Related]
16. Cancer-Associated Oxidase ERO1-α Regulates the Expression of MHC Class I Molecule via Oxidative Folding.
Kukita K; Tamura Y; Tanaka T; Kajiwara T; Kutomi G; Saito K; Okuya K; Takaya A; Kanaseki T; Tsukahara T; Hirohashi Y; Torigoe T; Furuhata T; Hirata K; Sato N
J Immunol; 2015 May; 194(10):4988-96. PubMed ID: 25870246
[TBL] [Abstract][Full Text] [Related]
17. Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Chen J; Jiang CC; Jin L; Zhang XD
Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673
[TBL] [Abstract][Full Text] [Related]
18. Role of the ERO1-PDI interaction in oxidative protein folding and disease.
Shergalis AG; Hu S; Bankhead A; Neamati N
Pharmacol Ther; 2020 Jun; 210():107525. PubMed ID: 32201313
[TBL] [Abstract][Full Text] [Related]
19. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
Jiao S; Xia W; Yamaguchi H; Wei Y; Chen MK; Hsu JM; Hsu JL; Yu WH; Du Y; Lee HH; Li CW; Chou CK; Lim SO; Chang SS; Litton J; Arun B; Hortobagyi GN; Hung MC
Clin Cancer Res; 2017 Jul; 23(14):3711-3720. PubMed ID: 28167507
[No Abstract] [Full Text] [Related]
20. Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas.
Spurny C; Kailayangiri S; Jamitzky S; Altvater B; Wardelmann E; Dirksen U; Hardes J; Hartmann W; Rossig C
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28868758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
